세계의 비오피오이드 통증 치료 시장 규모, 점유율 및 동향 분석 리포트 : 약물 클래스별(NSAIDs, 아세트아미노펜, 국소 마취약), 통증 유형별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2022-2030년)

Non-opioid Pain Treatment Market Growth & Trends:

The global non-opioid pain treatment market size is expected to reach USD 77.91 billion by 2030, registering a CAGR of 8.3% during the forecast period, according to a new report by Grand View Research, Inc. The growth can be attributed to an increase in the prevalence of inflammatory diseases coupled with the robust product pipeline of novel non-opioid analgesics. According to the Centers for Disease Control and Prevention (CDC), around 32.5 million people are living with osteoarthritis condition in the U.S. In addition, according to the Spondylitis Association of America, about 3.2 million adult people in the U.S. have some form of Spondyloarthritis.

Initiatives are undertaken by government & nonprofit organizations to promote the usage of safer alternatives to opioids such as NSAIDs to address the increasing demand for pain relieving medicines. For instance, in February 2022, the U.S.FDA issued draft guidelines to provide recommendations to pharmaceutical companies for developing NSAIDs for the treatment of acute pain lasting for 30 days. This initiative was a part of the government's "HHS Overdose Prevention Strategy" which focuses on the prevention, reduction, treatment, and recovery of patients from an opioid overdose. Such an initiative is projected to fuel demand for NSAID drugs over the forecast period.

Key market players are aggressively developing innovative techniques to meet the growing demand for NSAIDs for the management of pain. For instance, in June 2021, the University of Arizona developed oxytocin analogs for the treatment of patients suffering from. It is a bioavailable non-opioid pain relief product with the potential for inhaled administration. The development of such an innovative product is anticipated to drive non-opioid analgesics treatment market growth.

In September 2022, the U.S. FDA recommended avoiding non-opioid analgesics treatment in pregnancy at 20 weeks due to the high chances of kidney problems in unborn babies. Such initiatives from governments may limit the prescription of NSAIDs, thereby, restraining non-opioid pain treatment market growth.

Companies are adopting strategies such as new product development, launches, and partnerships to increase the penetration of non-opioid analgesic products. For instance, in March 2022, Vertex Pharmaceuticals announced positive results of its phase 2 clinical trial non-opioid pill that showed a significant reduction in post-operative acute pain. Successful completion of trial and subsequent approval of products is anticipated to drive non-opioid analgesics treatment market growth during the forecast period.

The market is highly competitive and the competition in the market is expected to be high during the forecast period due to the presence of a large number of players. Key companies manufacturing generic NSAID products include GSK plc., Sun Pharmaceutical Industries Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Johnson & Johnson Services, Inc., amongst others.

Non-opioid Pain Treatment Market Report Highlights:

• In 2021, the NSAIDs segment accounted for the largest market share and is anticipated to maintain its dominance over the forecast period owing to the high demand for pain treatment and the commercialization of multiple NSAIDs in recent years

• Chronic pain was the accounted for highest share in 2021. Factors such as increasing product approvals, the high incidence rate of chronic pain, and high R&D initiatives for launching innovative NSAIDs products are leading to its dominance

• Based on route of administration type, the oral segment accounted for the highest share in 2021 owing to the easy administration and wide availability of orally administered NSAIDs products in the market

• Based on the distribution channel, retail pharmacies are expected to dominate the market with a 53.98% share in 2021. This dominance can be attributed to the presence of a large number of generic NSAIDs and their easy accessibility to patients due to the large presence of retail pharmacies network

• Asia Pacific region is expected to experience the fastest growth during the forecast period owing to an increase in penetration of NSAIDs products, rise in disposable income, and high disease prevalence of inflammatory diseases in developing countries

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment Scope
  • 1.1.2 Regional Scope
  • 1.1.3 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database:
  • 1.3.2 Gvr's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach: Commodity Flow Approach
• 1.7 Research Assumptions
• 1.8 List of Secondary Sources
• 1.9 List of Abbreviations
• 1.10 Objectives
  • 1.10.1 Objective 1
  • 1.10.2 Objective 2
  • 1.10.3 Objective 3
  • 1.10.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Outlook

Chapter 3 Non-Opioid Pain Treatment Market Variables, Trends, and Scope

• 3.1 Penetration and Growth Prospect Mapping
• 3.2 Market Driver Analysis
  • 3.2.1 High Prevalence Of Chronic & Inflammatory Diseases Globally
  • 3.2.2 Increasing Product Approvals And Launches
  • 3.2.3 Supportive Regulatory And Reimbursement Policies
• 3.3 Market Restraint Analysis
  • 3.3.1 Misuse Of Product
  • 3.3.2 Side-Effects Associated With Use Of Nsaids
• 3.4 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
• 3.5 Industry Analysis - Porter's

Chapter 4 Non-Opioid Pain Treatment Market: Segment Analysis, by Drug Class, 2018 - 2030 (USD Million)

• 4.1 Definitions and Scope
• 4.2 Non-Opioid Pain Treatment Market: Drug Class Movement Analysis
• 4.3 NSAIDs
  • 4.3.1 Nsaids Market, 2018 - 2030 (USD Million)
  • 4.3.2 Selective Cox-2 Inhibitors Market, 2018 - 2030 (USD Million)
    • 4.3.2.1 Nsaids Market, 2018 - 2030 (USD Million)
  • 4.3.3 Non-Selective Nsaidsmarket, 2018 - 2030 (USD Million)
    • 4.3.3.1 Nsaids Market, 2018 - 2030 (USD Million)
• 4.4 Acetaminophen
  • 4.4.1 Acetaminophen Market, 2018 - 2030 (USD Million)
• 4.5 Local Anesthetics
  • 4.5.1 Local Anesthetics Market, 2018 - 2030 (USD Million)
• 4.6 Others
  • 4.6.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 Non-Opioid Pain Treatment Market: Segment Analysis, by Pain Type, 2018 - 2030 (USD Million)

• 5.1 Definitions & Scope
• 5.2 Non-Opioid Pain Treatment Market: Pain Type Movement Analysis
• 5.3 Chronic Pain
  • 5.3.1 Chronic Market, 2018 - 2030 (USD Million)
  • 5.3.2 Neuropathic Pain Market, 2018 - 2030 (USD Million)
    • 5.3.2.1 Neuropathic Pain Market, 2018 - 2030 (USD Million)
  • 5.3.3 Inflammatory Conditions Market, 2018 - 2030 (USD Million)
    • 5.3.3.1 Neuropathic Pain Market, 2018 - 2030 (USD Million)
• 5.4 Post-Operative Pain
  • 5.4.1 Post-Operative Pain Market, 2018 - 2030 (USD Million)
• 5.5 Cancer Pain
  • 5.5.1 Cancer Pain Market, 2018 - 2030 (USD Million)
• 5.6 Others
  • 5.6.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Non-Opioid Pain Treatment Market: Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)

• 6.1 Definitions and Scope
• 6.2 Non-Opioid Pain Treatment Market: Route of Administration Movement Analysis
• 6.3 Oral
  • 6.3.1 Oral Market, 2018 - 2030 (USD Million)
• 6.4 Topical
  • 6.4.1 Topical Market, 2018 - 2030 (USD Million)
• 6.5 Injectable
  • 6.5.1 Injectable Market, 2018 - 2030 (USD Million)
• 6.6 Others
  • 6.6.1 Others Market, 2018 - 2030 (USD Million)

Chapter 7 Non-Opioid Pain Treatment Market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million) ('000)

• 7.1 Non-Opioid Pain Treatment Market: Distribution Channel Movement Analysis
• 7.2 Hospital Pharmacy
  • 7.2.1 Hospital Pharmacy Market, 2018 - 2030 (USD Million)
• 7.3 Retail Pharmacy
  • 7.3.1 Retail Pharmacy Market, 2018 - 2030 (USD Million)
• 7.4 Others
  • 7.4.1 Others Market, 2018 - 2030 (USD Million)

Chapter 8 Non-Opioid Pain Treatment Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

• 8.1 Market Share Analysis
• 8.2 Regional Market Share Analysis, 2021 & 2030
• 8.3 Regional Market Snapshot
• 8.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
  • 8.4.1 North America
    • 8.4.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.4.1.2 U.S.
    • 8.4.1.2.1 U.S. Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.1.3 Canada
    • 8.4.1.3.1 Canada Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
  • 8.4.2 Europe
    • 8.4.2.1 Europe Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.2.2 U.K.
    • 8.4.2.2.1 U.K. Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.2.3 Germany
    • 8.4.2.3.1 Germany Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.2.4 Spain
    • 8.4.2.4.1 Spain Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.2.5 France
    • 8.4.2.5.1 France Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.2.6 Italy
    • 8.4.2.6.1 Italy Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
  • 8.4.3 Asia Pacific
    • 8.4.3.1 Asia Pacific Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.3.2 Japan
    • 8.4.3.2.1 Japan Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.3.3 China
    • 8.4.3.3.1 China Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.3.4 India
    • 8.4.3.4.1 India Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.3.5 South Korea
    • 8.4.3.5.1 South Korea Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.3.6 Australia
    • 8.4.3.6.1 Australia Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
  • 8.4.4 Latin America
    • 8.4.4.1 Latin America Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.4.2 Brazil
    • 8.4.4.2.1 Brazil Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.4.3 Mexico
    • 8.4.4.3.1 Mexico Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.4.4 Argentina
    • 8.4.4.4.1 Argentina Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
  • 8.4.5 MEA
    • 8.4.5.1 MEA Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.5.2 South Africa
    • 8.4.5.2.1 South Africa Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.5.3 Saudi Arabia
    • 8.4.5.3.1 Saudi Arabia Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)
    • 8.4.5.4 UAE
    • 8.4.5.4.1 UAE Non-Opioid Pain Treatment Market, 2018 - 2030 (USD Million)

Chapter 9 Non-Opioid Pain Treatment Market: Competitive Analysis

• 9.1 Recent Developments and Impact Analysis, by Key Market Participants
  • 9.1.1 New Product Launches
  • 9.1.2 Mergers And Acquisitions
  • 9.1.3 Partnerships And Strategic Collaboration
  • 9.1.4 Conferences And Campaigns
• 9.2 Company Categorization
  • 9.2.1 Innovators
  • 9.2.2 Market Leaders
  • 9.2.3 Heat Map Analysis
• 9.3 Vendor Landscape
  • 9.3.1 List Of Key Distributors And Channel Partners
  • 9.3.2 Key Customers
• 9.4 Key Company Market Share Analysis, 2021
• 9.5 Public Companies
  • 9.5.1 Company Market Position Analysis
  • 9.5.2 Company Market Position Analysis
  • 9.5.3 Competitive Dashboard Analysis
    • 9.5.3.1 Market Differentiators
• 9.6 Private Companies
  • 9.6.1 List Of Key Emerging Companies
  • 9.6.2 Regional Network Map
• 9.7 Company Profiles
  • 9.7.1 NOVARTIS AG
    • 9.7.1.1 Company overview
    • 9.7.1.2 Financial performance
    • 9.7.1.3 Product benchmarking
    • 9.7.1.4 Strategic initiatives
  • 9.7.2 TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    • 9.7.2.1 Company overview
    • 9.7.2.2 Financial performance
    • 9.7.2.3 Product benchmarking
    • 9.7.2.4 Strategic initiatives
  • 9.7.3 DR. REDDY'S LABORATORIES LTD
    • 9.7.3.1 Company overview
    • 9.7.3.2 Financial performance
    • 9.7.3.3 Product benchmarking
    • 9.7.3.4 Strategic initiatives
  • 9.7.4 SUN PHARMACEUTICAL INDUSTRIES LTD
    • 9.7.4.1 Company overview
    • 9.7.4.2 Financial performance
    • 9.7.4.3 Product benchmarking
    • 9.7.4.4 Strategic initiatives
  • 9.7.5 GSK PLC.
    • 9.7.5.1 Company overview
    • 9.7.5.2 Financial performance
    • 9.7.5.3 Product benchmarking
    • 9.7.5.4 Strategic initiatives
  • 9.7.6 PFIZER INC.
    • 9.7.6.1 Company overview
    • 9.7.6.2 Financial performance
    • 9.7.6.3 Product benchmarking
    • 9.7.6.4 Strategic initiatives
  • 9.7.7 PERRIGO COMPANY PLC.
    • 9.7.7.1 Company overview
    • 9.7.7.2 Financial performance
    • 9.7.7.3 Product benchmarking
    • 9.7.7.4 Strategic initiatives
  • 9.7.8 LNK INTERNATIONAL, INC.
    • 9.7.8.1 Company Overview
    • 9.7.8.2 Financial Performance
    • 9.7.8.3 Product Benchmarking
    • 9.7.8.4 Strategic Initiatives
  • 9.7.9 CIPLA INC.
    • 9.7.9.1 Company Overview
    • 9.7.9.2 Financial Performance
    • 9.7.9.3 Product Benchmarking
    • 9.7.9.4 Strategic Initiatives
  • 9.7.10 JOHNSON & JOHNSON SERVICES, INC.
    • 9.7.10.1 Company Overview
    • 9.7.10.2 Financial Performance
    • 9.7.10.3 Product Benchmarking
    • 9.7.10.4 Strategic Initiatives
  • 9.7.11 PACIRA PHARMACEUTICALS, INC.
    • 9.7.11.1 Company Overview
    • 9.7.11.2 Financial Performance
    • 9.7.11.3 Product Benchmarking
    • 9.7.11.4 Strategic Initiatives
  • 9.7.12 PIERREL
    • 9.7.12.1 Company Overview
    • 9.7.12.2 Financial Performance
    • 9.7.12.3 Product Benchmarking
    • 9.7.12.4 Strategic Initiatives